Joy C. Onyesoro
Research Subjects
Research Interests
Joy C. Onyesoro has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Adeniyi Thompson Adewumi
Department of Life and Consumer Sciences, Calabash Building, Room 02-026, University of South Africa, Johannesburg, South Africa
2 shared publications - Augustine Chidi Madueke
Drug Discovery Unit, Department of Biochemistry, University of Nigeria, Nsukka 410001, Nigeria
2 shared publications - Innocent Uzochukwu Okagu
Department of Biochemistry, Faculty of Biological Sciences, University of Nigeria, Nsukka, Nigeria
2 shared publications - Salerwe Mosebi
Department of Life and Consumer Sciences, Calabash Building, Room 02-026, University of South Africa, Johannesburg, South Africa
2 shared publications - Shadrach Chinecherem Eze
Department of Pharmaceutical and Medicinal Chemistry, College of Pharmacy, Afe Babalola University, Ado-Ekiti, Nigeria
2 shared publications - Stephen C. Nnemolisa
Drug Discovery Unit, Department of Biochemistry, University of Nigeria, Nsukka 410001, Nigeria
2 shared publications
Latest Publications
- Open Access
- 2 June 2026
- Published by MDPI AG in Biophysica
- Vol. 6 (3) , 47
Revisiting BACE-1: How Machine Learning and Molecular Dynamics Unveiled Potential Anti-Alzheimer’s Activity of a Cysteinyl Sulfoxide Derivative
Beta Secretase (BACE1) is a well-validated target for Alzheimer’s therapies, but there has been attrition in drug development. Herein, we leveraged machine learning (ML), virtual screening and molecular dynamics (MD) to identify novel compounds with potential activity against BACE1. We developed ML algorithms to distinguish active and inactive compounds from public databases. Molecular docking and dynamics were used to explore the inhibition mechanism, thermodynamic stability, and the flap dynamics of the BACE1-ligand complexes. Random Forest Classifier (RF) showed excellent metrics (accuracy: 0.9807; F1 score: 0.9804; specificity 0.9977), compared to other models. Molecular docking with predicted actives revealed compounds BA1, BA2, and BA3 with strong affinity for BACE1. Compound BA2, a cysteinyl sulfoxide derivative, showed good stability (RMSD) during simulations (1.307 ± 0.109 Å) compared to Verubecestat (1.602 ± 0.159 Å). MMGBSA-based binding free energy (ΔGbind; kcal/mol) showed that BA2 (−33.820 ± 4.254) had comparatively lower energy than Verubecestat (−21.090 ± 6.183). BA2 maintained electrostatic interactions with the catalytic dyad (Asp36 and Asp232) and Thr76 of the flap. BA2 also maintained the flaps in a semi-open conformation (d0: 11.807 ± 0.401 Å) throughout the simulation. Our study clearly demonstrates the utility of ML in prioritization of compounds before molecular docking and MD in early phases of drug discovery.
- 2 June 2026
- Published by MDPI AG in Biophysica
- Vol. 6 (3) , 47
Open AccessRevisiting BACE-1: How Machine Learning and Molecular Dynamics Unveiled Potential Anti-Alzheimer’s Activity of a Cysteinyl Sulfoxide Derivative
Beta Secretase (BACE1) is a well-validated target for Alzheimer’s therapies, but there has been attrition in drug development. Herein, we leveraged machine learning (ML), virtual screening and molecular dynamics (MD) to identify novel compounds with potential activity against BACE1. We developed ML algorithms to distinguish active and inactive compounds from public databases. Molecular docking and dynamics were used to explore the inhibition mechanism, thermodynamic stability, and the flap dynamics of the BACE1-ligand complexes. Random Forest Classifier (RF) showed excellent metrics (accuracy: 0.9807; F1 score: 0.9804; specificity 0.9977), compared to other models. Molecular docking with predicted actives revealed compounds BA1, BA2, and BA3 with strong affinity for BACE1. Compound BA2, a cysteinyl sulfoxide derivative, showed good stability (RMSD) during simulations (1.307 ± 0.109 Å) compared to Verubecestat (1.602 ± 0.159 Å). MMGBSA-based binding free energy (ΔGbind; kcal/mol) showed that BA2 (−33.820 ± 4.254) had comparatively lower energy than Verubecestat (−21.090 ± 6.183). BA2 maintained electrostatic interactions with the catalytic dyad (Asp36 and Asp232) and Thr76 of the flap. BA2 also maintained the flaps in a semi-open conformation (d0: 11.807 ± 0.401 Å) throughout the simulation. Our study clearly demonstrates the utility of ML in prioritization of compounds before molecular docking and MD in early phases of drug discovery.
- Open Access
- 23 March 2026
- Published by MDPI AG in Preprints.org
Revisiting BACE-1: How Machine Learning and Molecular Dynamics Unveiled Potential Anti-Alzheimer’s Activity of a Cysteinyl Sulfoxide Derivative
Beta Secretase (BACE-1) is a well-validated target for Alzheimer’s therapies, but have seen attrition in drug development. Herein, we leveraged machine learning (ML), virtual screening and molecular dynamics (MD) to identify novel compounds with potential activity against BACE1. We developed ML algorithms to distinguish active and inactive compounds from public databases. Molecular docking and MD (250ns) was used to explore the inhibition mechanism, thermodynamic stability, and the flap dynamics of the BACE1-ligand complexes. Random Forest Classifier (RF) showed excellent metrics (accuracy: 0.9807; F1 score: 0.9804; specificity 0.9977), compared to other models. Molecular docking with predicted actives revealed compounds BA1, BA2, and BA3 with strong affinity for the BACE1. Compound BA2, a cysteinyl sulfoxide derivative, showed good stability (RMSD) during simulations (1.307±0.109 Å) compared to Verubecestat (1.602±0.159Å). MMGBSA-based binding free energy (ΔGbind; kcal/mol) showed that BA2 (-33.820±4.254) had comparatively lower energy than Verubecestat (-21.090±6.183). BA2 maintained electrostatic interactions with the catalytic dyad (Asp36 & Asp232) and Thr76 of the flap. BA2 also maintained the flaps in a semi-open conformation (d0: 11.807 ± 0.401 Å) throughout the simulation. Our study clearly demonstrate the utility of ML in prioritization of compounds before molecular docking and MD in early phases of drug discovery.
- 23 March 2026
- Published by MDPI AG in Preprints.org
Open AccessRevisiting BACE-1: How Machine Learning and Molecular Dynamics Unveiled Potential Anti-Alzheimer’s Activity of a Cysteinyl Sulfoxide Derivative
Beta Secretase (BACE-1) is a well-validated target for Alzheimer’s therapies, but have seen attrition in drug development. Herein, we leveraged machine learning (ML), virtual screening and molecular dynamics (MD) to identify novel compounds with potential activity against BACE1. We developed ML algorithms to distinguish active and inactive compounds from public databases. Molecular docking and MD (250ns) was used to explore the inhibition mechanism, thermodynamic stability, and the flap dynamics of the BACE1-ligand complexes. Random Forest Classifier (RF) showed excellent metrics (accuracy: 0.9807; F1 score: 0.9804; specificity 0.9977), compared to other models. Molecular docking with predicted actives revealed compounds BA1, BA2, and BA3 with strong affinity for the BACE1. Compound BA2, a cysteinyl sulfoxide derivative, showed good stability (RMSD) during simulations (1.307±0.109 Å) compared to Verubecestat (1.602±0.159Å). MMGBSA-based binding free energy (ΔGbind; kcal/mol) showed that BA2 (-33.820±4.254) had comparatively lower energy than Verubecestat (-21.090±6.183). BA2 maintained electrostatic interactions with the catalytic dyad (Asp36 & Asp232) and Thr76 of the flap. BA2 also maintained the flaps in a semi-open conformation (d0: 11.807 ± 0.401 Å) throughout the simulation. Our study clearly demonstrate the utility of ML in prioritization of compounds before molecular docking and MD in early phases of drug discovery.